Novartis4h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Nature6y
Alcon licenses complement pathway inhibitor for macular degeneration
The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...
Fierce Biotech10d
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...
Nature5y
78 Differential Role of the Lectin Pathway of Complement Activation in Susceptibility to Neonatal Sepsis
Mannan-binding lectin (MBL), M-, L- and H-ficolin recognize microorganisms and activate the complement system via MBL-associated serine proteases (MASPs). We investigated lectin pathway cord blood ...
Medindia12m
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...